Abstract:Patients with esophageal cancer are often diagnosed at advanced stages, leading to poor prognosis. Biomarkers are needed to enable earlier detection as well as to aid in the prediction of prognosis, but to date these tools remain scarce. Thymidine kinase (TK1) has been shown to exhibit altered expression levels in esophageal tumor cells, therefore this study sought to determine whether serum TK1 levels are also altered and, if so, to assess the utility of TK1 as a biomarker in esophageal squamous cell carcinoma. Eighty patients with esophageal squamous cell carcinoma were included as the case group and 80 healthy persons were selected as the control group. Serum TK1 levels, postoperatively for cancer patients, were detected by chemiluminescence. Follow-up was performed for cancer patients to determine the progression free survival (PFS) and overall survival (OS). Serum TK1 levels were significantly higher in cases of esophageal cancer than in healthy control individuals (t=7.235, P<0.05). When cancer cases were sub-divided into lower and higher serum TK1 levels, based on the mean level of 3.38 pmol/L, statistically significant differences in TNM stage, tumor differentiation, and lymph node metastasis were observed between patients with ≥3.38 pmol/L and <3.38 pmol/L (χ(2)=28.134, 3.187, 7.234, P<0.05). The average OS of all esophageal cancer patients was 30.13 months, and the average PFS was 24.73 months. However, when the cases were divided by serum TK1 level, average OS of those with higher serum TK1 (≥3.38 pmol/L) was significantly lower (23.98 mo) than those with lower serum TK1 (32.96 mo) (χ(2)=5.439, P<0.05). Similarly, average PFS was significantly lower in patients with higher serum TK1 (17.65 mo versus 27.62) (χ(2)=4.640, P<0.05). OS was correlated with TNM stage (hazard ratio, HR=3.116), degree of tumor differentiation (HR=0.427), lymph node metastasis (HR=0.535), and serum TK1 level (HR=1.913) (Wald χ(2)=6.782, 6.228, 4.562, 5.681, P<0.05). Similarly, PFS was correlated with TMN stage (HR=2.153), degree of tumor differentiation (HR=0.627), and serum TK1 level (HR=1.632) (Wald χ(2)=7.035, 5.335, 4.887, P<0.05). Thus, patients with esophageal squamous cell carcinoma exhibit higher circulating TK1 levels, consistent with findings of increased TK1 expression in tumor cells. Further, the correlation of serum TK1 levels with clinical features of esophageal cancer and with patient survival suggest that serum TK1 may serve as a valuable biomarker for predicting patient prognosis.

High Thymidine Kinase 1 (TK1) Expression is a Predictor of Poor Survival in Patients with Pt1 of Lung Adenocarcinoma

Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.

Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma

Thymidine Kinase 1 is a Potential Marker for Prognosis and Monitoring the Response to Treatment of Patients with Breast, Lung, and Esophageal Cancer and Non-Hodgkin's Lymphoma

Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker

The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

Assessing the Potential Prognostic and Immunological Role of TK1 in Prostate Cancer

Elevated Thymidine Kinase 1 in Serum Following Neoadjuvant Chemotherapy Predicts Poor Outcome for Patients with Locally Advanced Breast Cancer

Thymidine Kinase 1 Appears to Be a Marker for the Prognosis of Hepatocellular Carcinoma Based on a Large-Scale, Multicenter Study.

TKI Resistant-Based Prognostic Immune Related Gene Signature in LUAD, in Which FSCN1 Contributes to Tumor Progression.

Clinical significance of detecting serum thvmidine kinase 1 in diagnosis and prognosis evaluation of lung cancer

Serum Thymidine Kinase 1 Levels Correlate with Clinical Characteristics of Esophageal Squamous Cell Carcinoma.

Thymidine Kinase 1: A Proliferation Marker for Determining Prognosis and Monitoring the Surgical Outcome of Primary Bladder Carcinoma Patients

STK1p As a Prognostic Biomarker for Overall Survival in Non-Small-cell Lung Carcinoma, Based on Real-World Data

Increased Serum Level of Thymidine Kinase 1 Correlates with Metastatic Site in Patients with Malignant Melanoma

Expression of Thop1 and Its Relationship to Prognosis in Non-Small Cell Lung Cancer

Transketolase Serves As a Biomarker for Poor Prognosis in Human Lung Adenocarcinoma.

Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix

Transketolase-like protein 1 expression predicts poor prognosis in colorectal cancer

Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer

Positive Transforming Growth Factor-Β Activated Kinase-1 Expression Has an Unfavorable Impact on Survival in T3N1-3M0 Esophageal Squamous Cell Carcinomas.